



## Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 pm ET at the Marriot Marquis in New York City.

### Jefferies Healthcare Conference

**Date:** Wednesday, June 8<sup>th</sup>, 2022  
**Time:** 3:30 to 3:55 pm Eastern Time  
**Presenter:** Lawrence Blatt, Ph.D., MBA, CEO of Aligos  
**Webcast:** [Registration Link – Click Here](#)

A *replay* of the session will be available following the conference for 90-days through the Aligos investor section of the website <https://investor.aligos.com/>.

The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Jefferies representative to schedule one-on-one meetings with Aligos during the conference.

### **About Aligos**

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

### **Forward-Looking Statement**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic and the developing conflict between Russia and Ukraine. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

### **Media Contact**

Amy Jobe, Ph.D.  
LifeSci Communications  
+1 315 879 8192  
[ajobe@lifescicomms.com](mailto:ajobe@lifescicomms.com)

### **Investor Contact**

Corey Davis, Ph.D.  
LifeSci Advisors  
+1 212 915 2577  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)